Literature DB >> 3606061

Correlation between renal membrane binding and nephrotoxicity of aminoglycosides.

P D Williams, D B Bennett, C R Gleason, G H Hottendorf.   

Abstract

The kinetics of aminoglycoside binding to renal brush border and basolateral membrane vesicles from rat renal cortex were studied by using [3H]amikacin. [3H]amikacin binding to renal membranes was found to be a rapid, saturable process with a fourfold greater affinity for basolateral membranes than for brush border membranes (Kd basolateral = 607 microM; Kd brush border = 2,535 microM). Renal membranes prepared from immature rats (2 to 3 weeks old) exhibited a significantly lower affinity compared with membranes from adults (Kd basolateral = 2,262 microM; Kd brush border = 6,216 microM). Additionally, the inhibitory behavior of several aminoglycosides versus [3H]amikacin binding to brush border membranes revealed the following rank order of potency: neomycin greater than tobramycin approximately gentamicin approximately netilmicin greater than amikacin approximately neamine greater than streptomycin. The relative insensitivity of immature rats to aminoglycoside-induced nephrotoxicity in vivo and the comparative nephrotoxicity of the various aminoglycosides suggest that renal membrane-binding affinity is closely correlated to the nephrotoxic potential of these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606061      PMCID: PMC174778          DOI: 10.1128/AAC.31.4.570

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Renal extraction of gentamicin in anesthetized dogs.

Authors:  P J Chiu; A Brown; G Miller; J F Long
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

2.  In vitro uptake of gentamicin by rat renal cortical tissue.

Authors:  C H Hsu; T W Kurtz; J M Weller
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

Review 3.  Editorial: Intrarenal antibiotic distribution in health and disease.

Authors:  A Whelton; W G Walker
Journal:  Kidney Int       Date:  1974-09       Impact factor: 10.612

4.  Enzymes of plasma membranes of liver.

Authors:  A I Lansing; M L Belkhode; W E Lynch; I Lieberman
Journal:  J Biol Chem       Date:  1967-04-25       Impact factor: 5.157

5.  Possible involvement of cardiac Na+, K+-adenosine triphosphatase in the mechanism of action of cardiac glycosides.

Authors:  A Schwartz; J C Allen; S Harigaya
Journal:  J Pharmacol Exp Ther       Date:  1969-07       Impact factor: 4.030

6.  Nephrotoxicity of gentamicin.

Authors:  J C Kosek; R I Mazze; M J Cousins
Journal:  Lab Invest       Date:  1974-01       Impact factor: 5.662

7.  Interactions of neomycin and calcium in synaptosomal membranes and polyphosphoinostide monolayers.

Authors:  S Lodhi; N D Weiner; J Schacht
Journal:  Biochim Biophys Acta       Date:  1976-04-05

8.  Nephrotoxicity of gentamicin. Action on subcellular organelles and pharmacokinetics in the kidney.

Authors:  J Fabre; J P Fillastre; J P Morin; M Rudhardt
Journal:  Contrib Nephrol       Date:  1978       Impact factor: 1.580

9.  Recovery from aminoglycoside nephrotoxicity with continued drug administration.

Authors:  F C Luft; L I Rankin; R S Sloan; M N Yum
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

10.  Analysis of the pinocytic process in rat kidney. I. Isolation of pinocytic vesicles from rat kidney cortex.

Authors:  F Bode; H Pockrandt-Hemstedt; K Baumann; R Kinne
Journal:  J Cell Biol       Date:  1974-12       Impact factor: 10.539

View more
  15 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Agents that increase the permeability of the outer membrane.

Authors:  M Vaara
Journal:  Microbiol Rev       Date:  1992-09

3.  Limited predictability of amikacin clearance in extreme premature neonates at birth.

Authors:  Karel Allegaert; Brian J Anderson; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

4.  Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum.

Authors:  Ya-Ping Liu; Guo-Fu Hu; Yun-Xia Wu
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

5.  Angiogenin as a molecular target for the treatment of prostate cancer.

Authors:  Shuping Li; Soichiro Ibaragi; Guo-Fu Hu
Journal:  Curr Cancer Ther Rev       Date:  2011-05

6.  Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.

Authors:  Zhibo Gai; Michele Visentin; Christian Hiller; Evelin Krajnc; Tongzhou Li; Junhui Zhen; Gerd A Kullak-Ublick
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 7.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 8.  Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.

Authors:  Lili Chen; Guo-fu Hu
Journal:  Oral Oncol       Date:  2010-07-24       Impact factor: 5.337

9.  Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription.

Authors:  Soichiro Ibaragi; Norie Yoshioka; Shuping Li; Miaofen G Hu; Saori Hirukawa; Peter M Sadow; Guo-Fu Hu
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.

Authors:  Virginie Bottero; Sathish Sadagopan; Karen E Johnson; Sujoy Dutta; Mohanan Valiya Veettil; Bala Chandran
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.